Source:http://linkedlifedata.com/resource/pubmed/id/12439123
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
2002-11-19
|
pubmed:abstractText |
The prognosis of patients with oesophageal cancer is poor, with an overall 5-year survival rate below 15%. The best chance for cure of patients with oesophageal cancer is surgical resection. However, more than 50% of patients have inoperable disease and can only be palliated for dysphagia. Some of these patients participate in studies investigating the activity of single-agent or combination chemotherapy. We report a patient who was cured of metastatic adenocarcinoma in Barrett's oesophagus by six courses of ifosfamide, a chemotherapeutic agent with little or no activity in other patients with adenocarcinoma of the oesophagus or gastro-oesophageal junction. After a follow-up of 13 years and 7 months, no evidence of tumour recurrence was found, while biopsies from the Barrett's oesophagus revealed only low-grade dysplasia. This case obviously raises the question as to how patients with inoperable oesophageal carcinoma can sometimes be cured by chemotherapy alone.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:author | |
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1261-4
|
pubmed:dateRevised |
2009-10-16
|
pubmed:articleTitle |
Cure of Barrett's carcinoma by ifosfamide chemotherapy.
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, University Hospital Rotterdam - Dijkzigt, Rotterdam, The Netherlands (representing the Rotterdam Oesophageal Tumour Study Group). siersema@mdl.azr.nl
|